By Joe Van Acker ( November 5, 2014, 2:01 PM EST) -- Endocyte Inc.'s board of directors lied about an ineffective cancer drug at the heart of a $1 billion deal with Merck & Co. to inflate the company's stock ahead of a public offering, according to an investor's derivative suit recently filed in Indiana federal court....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.